Innovative Molecules

About Innovative Molecules

Innovative Molecules GmbH is a German biotechnology company established in 2016 and based in Munich, focusing on the discovery and development of treatments for diseases induced by the Herpes Simplex Virus (HSV). The company was founded by Prof. Dr. Gerald Kleymann and Thomas Hoffmann. Kleymann, who serves as CEO and head of science, brings over three decades of experience in antiviral discovery research and is credited with the discovery of the company's lead candidate, IM-250. Hoffmann, leveraging more than 25 years in the biotech sector, including a role as CFO of Phenex Pharmaceuticals, manages finance and business development.

The company's core focus is its lead product, IM-250, an orally administered helicase-primase inhibitor designed to treat both HSV-1 and HSV-2. This therapeutic works by blocking the unwinding of viral DNA, which is a critical step in its replication process. A key differentiator for IM-250 is its potential to affect the latent viral reservoir, which could significantly alter the natural course of the disease by reducing the frequency of recurrent outbreaks. The market for herpes treatments has seen limited therapeutic advancements over the past few decades, creating a significant medical need for more effective solutions.

Innovative Molecules operates on a business-to-business model, targeting healthcare providers, clinicians, and pharmaceutical distributors as its primary clients. Revenue is expected to be generated from the sale of IM-250, with pricing structured based on volume or contractual agreements with healthcare institutions. In June 2021, the company secured €20 million (approximately $24.3 million) in a Series A financing round led by EQT Life Sciences (formerly LSP). These funds are allocated to advance IM-250 through clinical trials. The company has successfully completed enrollment for its Phase 1b clinical trial as of June 2025, with results anticipated in the second half of the year.